BACKGROUND/AIMS: The aim was to examine added benefits of a Comprehensive, Individualized, @entity1 -Centered Management (CI-PCM) program to @entity3393 treatment. METHODS: This was a 28-week, clinician-blinded, randomized, controlled, parallel-group study, with a similar study population, similar eligibility criteria, and a similar design to the @entity3393 pivotal trial of Reisberg et al. [N Engl J Med 2003;348:1333-1341]. Twenty eligible community-residing @entity195 ( @entity195 ) subject-caregiver dyads were randomized to the CI-PCM program (n = 10) or to usual community care (n = 10). Primary outcomes were the New York University Clinician's Interview-Based Impression of Change Plus Caregiver Input (NYU-CIBIC-Plus), assessed by one clinician set, and an activities of daily living inventory, assessed by a separate clinician set at baseline and at weeks 4, 12, and 28. RESULTS: Primary outcomes showed significant benefits of the CI-PCM program at all post-baseline evaluations. Improvement on the NYU-CIBIC-Plus in the management group at 28 weeks was 2.9 points over the comparator group. The @entity3393 2003 trial showed an improvement of 0.3 points on this global measure in @entity3393 -treated versus placebo-randomized subjects at 28 weeks. Hence, globally, the management program intervention benefits were 967% greater than @entity3393 treatment alone. CONCLUSION: These results are approximately 10 times those usually observed with both nonpharmacological and pharmacological treatments and indicate substantial benefits with the management program for advanced @entity195 @entity1 .

Comprehensive, Individualized, @entity1 -Centered Management of Community-Residing @entity1 with Moderate-to-Severe XXXX : A Randomized Controlled Trial.

@entity1 :: ('9606', 'Species') :: ['Person', 'persons'] @entity3393 :: ('MESH:D008559', 'Chemical') :: ['memantine'] @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', 'Alzheimer disease']
@entity195 :: (MESH:D000544,Disease) :: ['Alzheimer Disease']
